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A recent study of hereditary prostate cancer has provided evidence for a prostate cancer–susceptibility locus,HPC20,
which maps to 20q13. To assess further the potential contribution of this locus to prostate cancer susceptibility,
we studied 172 unrelated families affected by prostate cancer, using 17 polymorphic markers across a 98.5-cM
segment of chromosome 20 that contains the candidate region. Parametric analysis, allowing for heterogeneity,
resulted in an overall HLOD score of 0.09 ( ) at D20S171, under the assumption of linkage in 6% ofPp .39
families. Mode-of-inheritance–free analysis of the entire data set resulted in a maximal score of 0.76 (LODZ lr
0.13; ) at the same location. The strongest evidence for linkage was seen in the subset of 16 black familiesPp .22
(LOD 0.86; ; ) between markers D20S893 and D20S120, near the putative location of HPC20.Z p 1.99 Pp .023lr
Although some positive results were observed, our linkage study does not provide statistically significant support
for the existence of a prostate cancer–susceptibility locus HPC20 at 20q13.
Prostate cancer (MIM 176807) is the most commonly
diagnosed cancer among men in the United States
(Greenlee et al. 2000) and the fourth-most-commonly
diagnosed cancer in men worldwide (Parkin 1998). De-
spite this high prevalence, understanding of disease eti-
ology is still emerging. Known risk factors for the disease
are advanced age, black race, and an affected father or
brother (Chan et al. 1998). Germline mutations account
for ∼5%–10% of cases, and the rest are likely sporadic
(Carter et al. 1992; Carter et al. 1993). A genetic basis
for prostate cancer is indicated by studies demonstrating
that the lifetime risk of developing prostate cancer in-
creases by a factor of two- to threefold when at least
one first-degree relative is affected (Steinberg et al. 1990;
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Narod et al. 1995). Having both a first- and a second-
degree affected family member may provide as much as
an eightfold increase in risk (Steinberg et al. 1990). Seg-
regation analyses suggest that, in a small proportion of
cases, a prostate cancer–susceptibility gene is passed in
an autosomal dominant mode of inheritance (Carter et
al. 1992; Gronberg et al. 1997; Schaid et al. 1998). How-
ever, epidemiologic studies show that affected brothers
confer a higher risk of prostate cancer than do affected
fathers, and that this result is consistent across multiple
racial groups (Monroe et al. 1995; Narod et al. 1995).
This pattern indicates possible X-linked or recessive
modes of prostate cancer inheritance. Thus, genetic-
epidemiology studies suggest that there likely will be
more than one locus that contributes to the inherited
predisposition to prostate cancer.
Five putative prostate cancer–predisposition genes
have been identified by means of family-based linkage
approaches: HPC1 (MIM 601518; Smith et al. 1996),
PCAP (MIM 602759; Berthon et al. 1998), and CAPB
(MIM 603688; Gibbs et al. 1999) on chromosome 1;
HPC2 (MIM 605367; Tavtigian et al. 2000) on chro-
mosome 17; and HPCX (MIM 300147; Xu et al. 1998)
on the X chromosome. A recent linkage study by Berry
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Table 1
Characteristics of Participating Families
Characteristic
No. of
Families
Average Age
(years)
at Diagnosis
of Genotyped
Affected
Individuals (SD)
Average No.
of Affected
Men per
Family (Range)
Average No.
of Affected
Men Genotyped
per Family
(Range)
All families 172 62.7 (9.43) 3.8 (2–14) 2.6 (2–7)
White 154 63.1 (9.31) 3.7 (2–13) 2.6 (2–7)
Black 16 59.7 (9.64) 5.1 (2–14) 2.5 (2–4)
Asian/Pacific Islander 2 56.4 (12.82) 5.0 (5) 2.0 (2)
!5 affected members 148 62.7 (9.60) 3.3 (2–4) 2.4 (2–4)
5 affected members 24 62.4 (8.63) 7.1 (5–14) 3.3 (2–7)
Average age at diagnosis !66 years 108 59.8 (8.98) 3.7 (2–14) 2.5 (2–5)
Average age at diagnosis 66 years 64 67.4 (8.14) 4.1 (3–12) 2.6 (2–7)
Male-to-male transmission 122 62.7 (9.86) 4.1 (2–14) 2.6 (2–7)
No male-to-male transmission 50 62.5 (8.26) 3.1 (2–6) 2.5 (2–5)
et al. (2000) of 162 families affected by prostate cancer
described evidence for a sixth prostate cancer predis-
position gene, termed “HPC20,” on 20q13. The families
studied in this report were identified at the Mayo Clinic
in Rochester, MN; 161 of these families were white, and
one family was of Hispanic descent.
The aim of this study is to confirm the potential con-
tribution of the HPC20 locus to prostate cancer suscep-
tibility in an independent set of families. Therefore, a
replication study was undertaken using 172 families af-
fected by prostate cancer who are participating in the
University of Michigan Prostate Cancer Genetics Project
(PCGP). The PCGP was initiated in 1995, with the goal
of defining the molecular basis of hereditary prostate
cancer.
Men with prostate cancer who have at least one living
affected relative were asked to participate in the PCGP
by providing a blood sample, extended family history
information, and access to medical records. All partic-
ipants gave written informed consent, and all research
protocols and consent forms were approved by the in-
stitutional review board at the University of Michigan.
Those families either with three or more confirmed cases
of prostate cancer in first- or second-degree relatives or
with two such cases occurring in men aged 55 years
were included in the current analysis. Blood samples
collected from affected individuals and from unaffected
individuals that were informative for linkage were used.
DNA was isolated from nucleated blood cells by use of
the Puregene kit (Gentra Systems).
The DNA samples from all 558 individuals (including
441 affected men) were genotyped using a panel of 17
polymorphic markers spanning 98.5 cM and containing
the HPC20 candidate region at 20q13 (near D20S887).
Markers were chosen and genotyping was performed as
described elsewhere (Berry et al. 2000). Marker allele
frequencies were estimated from the data using all gen-
otyped individuals.
Data were analyzed using both parametric and mode-
of-inheritance–free methods of linkage. Parametric link-
age in the presence of heterogeneity was assessed using
heterogeneity LOD (HLOD) scores. HLOD scores and
their accompanying estimates of the percentage of linked
families (a) were calculated using the statistical software
package GENEHUNTER PLUS, version 1.2 (Kruglyak
et al. 1996; Kong and Cox 1997) . These analyses require
the specification of a disease-transmission model. For
our study, we used a parametric model similar to that
used by Berry et al. (2000) for the localization of
HPC20. This parametric model (Model A) was intro-
duced by Smith et al. (1996); it specifies an autosomal
dominant mode of inheritance with a disease allele fre-
quency of .003. The penetrance rate among affected men
is .001 for noncarriers and 1.00 for carriers. In our
model, all unaffected men and all women are considered
uninformative (i.e., of unknown phenotype) for the anal-
ysis. HLODs follow a complex statistical distribution.
To obtain significance estimates for the observed
HLODs, the HLODs were first converted to a x2, where
. P values ( ) were then derived for2x p 4.6#HLOD P1
x2, using the x2 distribution with one df. The P value
for the HLOD score is (Far-.5# [1 (1 P )(1 P )]1 1
away 1993).
We performed multipoint mode-of-inheritance–free
linkage analyses using the computer software package
GENEHUNTER PLUS, version 1.2 (Kruglyak et al.
1996; Kong and Cox 1997). For these analyses, we util-
ized the statistic (Whittemore and Halpern 1994) andSall
the exponential likelihood-based allele-sharing model
(ASM). Results are reported in terms of the statistic,Z lr
the LOD score, and its associated one-sided P value.
Under the null hypothesis of no linkage, the statisticZ lr
is distributed asymptotically as a standard normal ran-
dom variable.
For inclusion in the analyses, 558 individuals from
172 families (see table 1) were genotyped. There were
Table 2
Summary of Parametric (Maximum HLOD) and Mode-of-Inheritance–Free (Maximum Multipoint LOD using ASM) Linkage Analysis Results
SUBSET n HLOD a
PARAMETRIC MODE-OF-INHERITANCE–FREE
Location
(cM)
(Nearest Marker) P
Location
(cM)
(Nearest Marker)
Multipoint
LOD Zlr P
Full group (all races) 172 .09 .06 96.5 (D20S171) .39 96.5 (D20S171) .13 .76 .22
White 154 .05 .05 96.5 (D20S171) .43 96.5 (D20S171) .084 .62 .27
Black 16 .25 .38 79.2 (D20S893–D20S120) .24 78.1 (D20S893–D20S120) .86 1.99 .023
!5 affected members 148 .20 .09 96.5 (D20S171) .28 96.5 (D20S171) .19 .93 .18
5 affected members 24 .08 .08 82.4 (D20S120) .39 32.2 (D20S186–D20S112) .35 1.27 .10
Average age at diagnosis!66 years 108 .03 .05 96.5 (D20S171) .46 96.5 (D20S171) .076 .59 .28
Average age at diagnosis 66 years 64 .13 .10 98.5 (D20S173) .34 98.5 (D20S173) .13 .77 .22
Male-to-male transmission 122 .19 .09 96.5 (D20S171) .29 96.5 (D20S171) .32 1.21 .12
No male-to-male transmission 50 .02 .06 29.4 (D20S186) .47 18.4 (D20S115) .020 .30 .38
!5 affected members and average age at diagnosis 66 years 54 .73 .28 98.5 (D20S173) .064 98.5 (D20S173) .41 1.38 .084
5 affected members and average age at diagnosis !66 years 13 .54 .43 80.3 (D20S893–D20S120) .11 78.1 (D20S893–D20S120) .29 1.16 .11
!5 affected and average age 66 years and no male-to-male transmission 18 .79 .50 7.9 (D20S889) .055 7.9 (D20S889) .49 1.51 .066
5 affected and average age !66 years and male-to-male transmission 10 .18 .25 96.5 (D20S171) .30 96.5 (D20S171) .18 .90 .18
!5 affected members and 66 years and male-to-male transmission 35 1.05 .41 98.5 (D20S173) .028 98.5 (D20S173) .62 1.69 .050
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Figure 1 Mode-of-inheritance–free linkage analysis on chromosome 20, showing scores calculated by the GENEHUNTER PLUS ASM,Zlr
for all families, and stratified by race. (Note that the two Hispanic families were excluded from the race stratifications.) In the report by Berry
et al. (2000), the maximum multipoint NPL Z score was observed at marker D20S887 when all families were analyzed together.
154 white, 16 black, and 2 Asian/Pacific Island families.
The average age at diagnosis among all affected indi-
viduals genotyped for analysis was 62.7 years.
Because prostate cancer is a heterogeneous disease,
both parametric and mode-of-inheritance–free linkage
analyses were performed on different stratifications of
the data, as well as on the entire sample of families. In
addition to race, families were stratified by criteria iden-
tical to those used by Berry et al. (2000). These criteria
are defined as the number of affected family members
(!5 vs. 5), average age at diagnosis (!66 years vs.66
years), and by presence or absence of evidence for male-
to-male transmission of prostate cancer within the fam-
ily. There were 28 bilineal families included in our re-
port; these families were included in the male-to-male
transmission category.
Results of both parametric and mode-of-inheri-
tance–free linkage analyses are summarized in table 2.
The overall maximum HLOD in the entire sample is 0.09
( ) at 96.5 cM, under the assumption of linkagePp .39
in 6% of families. Multipoint mode-of-inheritance–free
linkage analysis of all 172 families results in a maximum
score of 0.76 (LOD 0.13), with a corresponding one-Z lr
sided P value of .22 at marker D20S171 (map position
96.5 cM; see table 2 and fig. 1). After stratification by
race, marginally significant evidence for linkage is found
using mode-of-inheritance–free methods to analyze the
subset of 16 black families ( ; LOD 0.86; one-Z p 1.99lr
sided P value .023; between markers D20S893 and
D20S120). The location of this peak score is withinZ lr
4 cM of the marker that gave the most evidence for
linkage in the entire data set in the initial HPC20 report
(Berry et al. 2000; see fig. 1). It is of note that 6 black
families from this data set provided the strongest evi-
dence for linkage in our HPC1 confirmatory study (Coo-
ney et al. 1997), whereas 11 of these 16 families did not
support linkage to HPCX in our confirmatory report on
this locus (Lange et al. 1999). Further analysis of these
families, using data from multiple hereditary prostate
cancer candidate regions, is in progress.
When the 172 families are stratified by number of
affected members, average age at diagnosis, or male-to-
male transmission, no statistically significant evidence
for linkage to markers within the likely HPC20 candi-
date was observed in any of the subgroups, using either
parametric or mode-of-inheritance–free methods (see ta-
ble 2). In the original report by Berry et al. (2000), the
strongest evidence for linkage occurred in the subset of
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Figure 2 Mode-of-inheritance–free linkage analysis on chromosome 20, showing scores calculated by the GENEHUNTER PLUS ASMZlr
for all families and stratified by number of family members affected with prostate cancer; average age, within a family, at diagnosis of prostate
cancer; and male-to-male transmission of prostate cancer. The maximum multipoint NPL Z scores in the stratified analyses performed by Berry
et al. (2000) were located between markers D20S178 and D20S100.
families defined by no male-to-male transmission, fewer
than five affected members, and age at onset 66 years.
In the current study, parametric analysis provides some
evidence for linkage in the 18 families meeting these
same criteria; however, the significance is marginal
(HLOD 0.79 under the assumption that 50% of families
are linked; at marker D20S889). Results fromPp .055
the mode-of-inheritance–free analysis are consistent with
the parametric findings ( ; LOD 0.49;Z p 1.51 Pplr
at marker D20S889). Interestingly, however, the.066
maximum scores in our data set are at a marker 69.1
cM proximal to the marker with the maximum NPL
score (D20S893) in the similarly defined subset reported
by Berry et al. (2000). Our linkage results in this sub-
group are negative in the putative region on 20q13 (near
marker D20S887) that contains HPC20 (see fig. 2).
Other strata produce some evidence for chromosome 20
linkage, but not in the HPC20 candidate interval. For
example, the 35 families with fewer than five affected
members, age at diagnosis 66 years, and male-to-male
transmission have a maximum HLOD of 1.05 at marker
D20S173 ( ; ), which is ∼20 cM distalap 0.41 Pp .028
to the most likely HPC20 location.
In our study, neither parametric nor mode-of-inheri-
tance–free linkage methods show significant support for
the existence of a prostate cancer–susceptibility locus at
20q13. This may be explained in part by differences
between the two studies in sample characteristics in-
cluding family size, age of prostate cancer diagnosis, and
ethnic composition. The University of Michigan PCGP
families report significantly fewer affected members per
family (3.8 vs. 4.4; ). Furthermore, by compar-P ! .001
ison of the average of the mean age at diagnosis within
families, the PCGP families were diagnosed at a signif-
icantly younger age (64.0 years vs. 66.5 years; P !
). Although both studies recruited families of pros-.0001
tate cancer patients identified at a tertiary-care medical
center, the Michigan sample also includes families re-
ferred to the study from other sources within Michigan,
as well as from elsewhere in the United States. Increased
genetic heterogeneity in the Michigan sample is sup-
ported by the presence of black families, whereas all of
the families in the Mayo study were white, with the
exception of one Hispanic family.
Although it is possible that the findings by Berry et
al. (2000) represent a false-positive result, it is also pos-
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sible that their findings are real but will require a much
larger sample size to replicate the linkage findings. It has
been shown that, when a complex trait is caused by
multiple susceptibility loci, the sample size needed for
initial detection of linkage to any one of the loci is much
smaller than the sample size required to confirm a par-
ticular chromosomal region (Suarez et al. 1994). Anal-
yses using the computer program SIMLINK (Ploughman
and Boehnke 1989) suggest that there is modest power
to detect linkage to HPC20 in our entire collection of
families. Using our parametric linkage model, we esti-
mate that we have 20% power to measure an overall
HLOD of 1.0, conditional on the value of a, the pro-
portion of families linked, reported by Berry et al.
(2000). We have better power to detect an HLOD of
1.0 when analyzing pedigrees with fewer than five af-
fected members (0.67), average age at diagnosis !66
(0.70), and no male-to-male transmission (0.80), util-
izing the corresponding values for a described in the
original HPC20 report. However, these power estimates
must be interpreted with caution, because the proportion
of linked families (a) derived from the data of Berry et
al. (2000) is not likely to be an accurate measure for
other sets of pedigrees. Furthermore, although Model A
(Smith et al. 1996) is a valid (unbiased) model for linkage
analysis, it is not likely to be plausible for a complex
disease. Decreasing the value of a or decreasing the rel-
ative risk between carriers and noncarriers likely will
reduce the estimated power to detect linkage.
With the exception of the linkage result observed in
the black families, our data fail to provide supportive
evidence for the existence of a prostate cancer–sus-
ceptibility locus at chromosome 20q13. However, the
data presented here follow some of the same trends with
stratification as were observed in the original study (i.e.,
increased evidence of linkage in smaller families affected
by prostate cancer with later disease onset), suggesting
that HPC20 may represent a low-penetrance prostate
cancer–predisposition gene. Additional studies of this
region in other populations, using large sets of data, are
necessary to validate HPC20 as a prostate cancer–
susceptibility locus.
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